{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:32:25Z","timestamp":1761093145615,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002560","name":"Soonchunhyang University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.urolonc.2021.07.002","type":"journal-article","created":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T17:06:21Z","timestamp":1627146381000},"page":"6.e11-6.e19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk of cardiovascular intervention after androgen deprivation therapy in prostate cancer patients with a prior history of ischemic cardiovascular and cerebrovascular disease: A nationwide population-based cohort study"],"prefix":"10.1016","volume":"40","author":[{"given":"Do Kyung","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Sun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju-Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon Soo","family":"Hah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee Soo","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Heon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang Su","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2021.07.002_bib0001","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/cncr.31826","article-title":"Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer","volume":"125","author":"Borno","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0002","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0003","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/jnci\/djm168","article-title":"Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality","volume":"99","author":"Tsai","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0004","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.eururo.2014.11.039","article-title":"Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis","volume":"68","author":"Bosco","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0005","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00345-014-1439-6","article-title":"Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis","volume":"33","author":"Carneiro","year":"2015","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0006","article-title":"Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies","volume":"9","author":"Zhao","year":"2014","journal-title":"PloS one"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0007","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/11594540-000000000-00000","article-title":"Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care","volume":"34","author":"Mart\u00edn-Merino","year":"2011","journal-title":"Drug Saf"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0008","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2008.20.0923","article-title":"Impact of androgen deprivation therapy on cardiovascular disease and diabetes","volume":"27","author":"Alibhai","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0009","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.2007.13.9881","article-title":"Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610","volume":"26","author":"Roach","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0010","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2007.12.3752","article-title":"Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31","volume":"27","author":"Efstathiou","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0011","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0012","first-page":"289","article-title":"Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial","volume":"299","author":"D'Amico","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0013","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials","volume":"306","author":"Nguyen","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0014","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.amjmed.2012.01.014","article-title":"An international model to predict recurrent cardiovascular disease","volume":"125","author":"Wilson","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0015","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1200\/JCO.2010.29.1567","article-title":"Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden","volume":"28","author":"Van Hemelrijck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0016","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.eururo.2013.02.002","article-title":"Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study","volume":"65","author":"Jespersen","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0017","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3346\/jkms.2017.32.5.718","article-title":"Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data","volume":"32","author":"Kim","year":"2017","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0018","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.fertnstert.2006.11.125","article-title":"The use and misuse of matching in case-control studies: the example of polycystic ovary syndrome","volume":"88","author":"Bloom","year":"2007","journal-title":"Fertil Steril"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0019","doi-asserted-by":"crossref","first-page":"684","DOI":"10.2105\/AJPH.43.6_Pt_1.684","article-title":"Matching in analytical studies","volume":"43","author":"Cochran","year":"1953","journal-title":"Am J Public Health"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0020","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/hrt.2003.017269","article-title":"Interpretation of observational studies","volume":"90","author":"Jepsen","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0021","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12874-017-0405-6","article-title":"Statistical methods for elimination of guarantee-time bias in cohort studies: a simulation study","volume":"17","author":"Cho","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0022","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0090-4295(02)01560-1","article-title":"Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer","volume":"60","author":"Meng","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0023","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/11594540-000000000-00000","article-title":"Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care","volume":"34","author":"Martin-Merino","year":"2011","journal-title":"Drug Saf"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0024","doi-asserted-by":"crossref","first-page":"E82","DOI":"10.1111\/bju.12732","article-title":"The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study","volume":"114","author":"Gandaglia","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0025","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.urolonc.2015.05.030","article-title":"Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanisms","volume":"33","author":"Tivesten","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0026","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1743-6109.2010.01991.x","article-title":"Testosterone and metabolic syndrome: a meta-analysis study","volume":"8","author":"Corona","year":"2011","journal-title":"J Sex Med"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0027","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/hrt.2010.210757","article-title":"Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis","volume":"97","author":"Ruige","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0028","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/MED.0000000000000057","article-title":"Testosterone, aging and survival: biomarker or deficiency","volume":"21","author":"Shores","year":"2014","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0029","first-page":"1518","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"104","author":"Keating","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0030","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0031","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality","volume":"57","author":"Sundararajan","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0032","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2017.03.002","article-title":"Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data","volume":"77","author":"Scailteux","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0033","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1097\/JU.0000000000000384","article-title":"Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease","volume":"202","author":"Margel","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0034","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.eururo.2018.11.022","article-title":"Androgen deprivation therapies and changes in comorbidity: a comparison of gonadotropin-releasing hormone agonists and antiandrogen monotherapy as primary therapy in men with high-risk prostate cancer","volume":"75","author":"Beckmann","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.07.002_bib0035","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","article-title":"Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist","volume":"65","author":"Albertsen","year":"2014","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921003021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921003021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:22:51Z","timestamp":1761042171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143921003021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1078143921003021"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.07.002","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of cardiovascular intervention after androgen deprivation therapy in prostate cancer patients with a prior history of ischemic cardiovascular and cerebrovascular disease: A nationwide population-based cohort study","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}